WO2005072893A8 - Functionalized colloidal metal compositions and methods - Google Patents

Functionalized colloidal metal compositions and methods

Info

Publication number
WO2005072893A8
WO2005072893A8 PCT/US2005/003454 US2005003454W WO2005072893A8 WO 2005072893 A8 WO2005072893 A8 WO 2005072893A8 US 2005003454 W US2005003454 W US 2005003454W WO 2005072893 A8 WO2005072893 A8 WO 2005072893A8
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
colloidal metal
metal compositions
functionalized
Prior art date
Application number
PCT/US2005/003454
Other languages
French (fr)
Other versions
WO2005072893A1 (en
Inventor
Giulio F Paciotti
Lawrence Tamarkin
Original Assignee
Cytimmune Sciences Inc
Giulio F Paciotti
Lawrence Tamarkin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytimmune Sciences Inc, Giulio F Paciotti, Lawrence Tamarkin filed Critical Cytimmune Sciences Inc
Priority to EP05722715A priority Critical patent/EP1715971A4/en
Priority to AU2005209318A priority patent/AU2005209318B2/en
Priority to CA002554755A priority patent/CA2554755A1/en
Priority to JP2006551620A priority patent/JP4833862B2/en
Publication of WO2005072893A1 publication Critical patent/WO2005072893A1/en
Publication of WO2005072893A8 publication Critical patent/WO2005072893A8/en
Priority to IL177075A priority patent/IL177075A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites

Abstract

The present invention comprises methods and compositions for making functionalized/reactive colloidal metal compositions and the uses thereof. The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, these vector compositions comprise a functionalized/reactive colloidal metal, and an agent. The invention also comprises methods and compositions for the treatment of cancer.
PCT/US2005/003454 2004-01-28 2005-01-28 Functionalized colloidal metal compositions and methods WO2005072893A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP05722715A EP1715971A4 (en) 2004-01-28 2005-01-28 Functionalized colloidal metal compositions and methods
AU2005209318A AU2005209318B2 (en) 2004-01-28 2005-01-28 Functionalized colloidal metal compositions and methods
CA002554755A CA2554755A1 (en) 2004-01-28 2005-01-28 Functionalized colloidal metal compositions and methods
JP2006551620A JP4833862B2 (en) 2004-01-28 2005-01-28 Functionalized colloidal metal compositions and methods
IL177075A IL177075A (en) 2004-01-28 2006-07-25 Functionalized colloidal metal compositions and methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54007504P 2004-01-28 2004-01-28
US60/540,075 2004-01-28

Publications (2)

Publication Number Publication Date
WO2005072893A1 WO2005072893A1 (en) 2005-08-11
WO2005072893A8 true WO2005072893A8 (en) 2005-10-06

Family

ID=34826180

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/003454 WO2005072893A1 (en) 2004-01-28 2005-01-28 Functionalized colloidal metal compositions and methods

Country Status (8)

Country Link
US (1) US20050175584A1 (en)
EP (1) EP1715971A4 (en)
JP (1) JP4833862B2 (en)
CN (1) CN1960825A (en)
AU (1) AU2005209318B2 (en)
CA (1) CA2554755A1 (en)
IL (1) IL177075A (en)
WO (1) WO2005072893A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2309604C (en) * 1997-11-10 2010-01-12 Cytimmune Sciences, Inc. Compositions and methods for targeted delivery of factors
US7229841B2 (en) 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US20100015068A1 (en) * 2006-07-06 2010-01-21 Massachusetts Institute Of Technology Methods and Compositions For Altering Biological Surfaces
US9056129B2 (en) * 2007-02-09 2015-06-16 Northeastern University Precision-guided nanoparticle systems for drug delivery
JP5142251B2 (en) * 2007-04-20 2013-02-13 国立大学法人大阪大学 Composite particles using gold iron oxide particles and MRI contrast agent
US8877156B2 (en) 2007-06-26 2014-11-04 New York University Contrast agents anchored by thiols on nanoparticles
JP2009057311A (en) * 2007-08-31 2009-03-19 Nof Corp Metal salt-reducing agent, method for producing metal fine particles, method for producing metal fine particle-liposome composite, and material for medical care
US20090104114A1 (en) * 2007-09-21 2009-04-23 Cytimmune Sciences, Inc. Nanotherapeutic Colloidal Metal Compositions and Methods
US20110014118A1 (en) * 2007-09-21 2011-01-20 Lawrence Tamarkin Nanotherapeutic colloidal metal compositions and methods
EP2205282A2 (en) 2007-09-24 2010-07-14 Bar-Ilan University Polymer nanoparticles coated by magnetic metal oxide and uses thereof
US7960145B2 (en) 2007-11-08 2011-06-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
AU2009209541A1 (en) * 2008-01-30 2009-08-06 Pharma Mar, S.A. Improved antitumoral treatments
WO2009109649A1 (en) * 2008-03-07 2009-09-11 Pharma Mar, S.A. Improved antitumoral treatments
US20120076848A1 (en) * 2009-07-22 2012-03-29 Kambiz Thomas Moazed Method and system for effecting changes in pigmented tissue
US8784895B2 (en) 2011-03-15 2014-07-22 Northwestern University Multifunctional metal nanoparticles having a polydopamine-based surface and methods of making and using the same
US9095625B2 (en) 2012-08-31 2015-08-04 University Of Massachusetts Graft-copolymer stabilized metal nanoparticles
JP2016511747A (en) 2013-01-04 2016-04-21 マサチューセッツ インスティテュート オブ テクノロジー Drug delivery to tissues based on nanoparticle surface binding
GB2510587B (en) * 2013-02-07 2020-05-20 Orthopaedic Res Uk Biospecific agents for bone
KR101681114B1 (en) * 2015-01-23 2016-12-01 한국과학기술연구원 Surface modified nanoparticles, and colorimetric detection sensor for zinc ion using the same

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3145144A (en) * 1951-08-09 1964-08-18 Takeda Pharmacentical Ind Ltd Process for manufacturing chromium treated vaccines
US2768958A (en) * 1954-04-08 1956-10-30 Goodrich Co B F Colloidal dispersions of heavy metal compounds
US2785153A (en) * 1954-09-13 1957-03-12 Crookes Barnes Lab Inc Silver protein
US3149036A (en) * 1961-10-16 1964-09-15 Merck & Co Inc Adjuvant vaccine with aluminum monostearate, mannide monooleate, vegetable oil, and an aqueous phase immunolgical agent
US3269912A (en) * 1963-04-08 1966-08-30 Boehringer & Soehne Gmbh Aluminum oxide depot vaccines
US3399263A (en) * 1965-04-12 1968-08-27 American Cyanamid Co Stable adjuvant emulsion compositions comprising the hydrated reaction products of a methallic cation and a fatty acid
US3651211A (en) * 1967-10-16 1972-03-21 Lockheed Aircraft Corp Virus inactivation
US3819820A (en) * 1968-07-31 1974-06-25 J Lorina Irradiated substance and compound and method of preparing the same
US3577523A (en) * 1969-03-07 1971-05-04 Miles Lab Water-insoluble antigenic substances and method of preparing the same and antigenic depot agents incorporating such substances
US3531565A (en) * 1969-09-25 1970-09-29 American Cyanamid Co Stable adjuvant emulsion compositions comprising hydrated salts of a polyvalent metallic cation and a higher fatty acid
US4177263A (en) * 1972-02-28 1979-12-04 Research Corporation Anti-animal tumor method
US4339437A (en) * 1976-12-27 1982-07-13 Research Corporation Anti-tumor method
US4016252A (en) * 1972-04-06 1977-04-05 Institut Pasteur Calcium phosphate gel for adsorbing vaccines
US4053587A (en) * 1973-04-13 1977-10-11 Research Corporation Method of treating viral infections
US4197237A (en) * 1973-06-01 1980-04-08 Syva Company Antibodies to nitrogen derivatives of benzoyl ecgonine antigenic conjugates thereof
US3983228A (en) * 1973-08-28 1976-09-28 Merck & Co., Inc. Water-in-oil adjuvant composition
US3919413A (en) * 1973-10-12 1975-11-11 Univ Nebraska Vaccine for neonatal calf diarrhea
US4069313A (en) * 1974-11-19 1978-01-17 Merck & Co., Inc. Water-in-oil adjuvant composition
US4218436A (en) * 1977-09-21 1980-08-19 The Upjohn Company Compounds and methods
US4197286A (en) * 1977-09-27 1980-04-08 Southwest Research Institute Testosterone derivatives and assay method
US4329281A (en) * 1978-06-05 1982-05-11 Hoffmann-La Roche Inc. Hapten compositions
US4196185A (en) * 1978-06-05 1980-04-01 Hoffmann-La Roche Inc. Immunoassay for phencyclidine
US4215036A (en) * 1978-08-15 1980-07-29 Research Corporation Modified grass pollen antigens
US4346074A (en) * 1978-08-24 1982-08-24 National Research Development Corp. Pasteurellosis vaccines
US4213964A (en) * 1978-12-07 1980-07-22 Miles Laboratories, Inc. Diphenylhydantoin antibodies
US4487780A (en) * 1979-09-18 1984-12-11 Scheinberg Israel H Method of treatment of rheumatoid arthritis
US4332787A (en) * 1980-06-23 1982-06-01 The Massachusetts General Hospital Assay for beta-adrenergic antagonists and antibody therefor
US4330530A (en) * 1980-12-22 1982-05-18 The Procter & Gamble Company Anti-arthritic compositions and method using gold salts and organophosphonates
US4594325A (en) * 1981-03-26 1986-06-10 The Regents Of The University Of Calif. High fusion frequency fusible lymphoblastoid cell line
US4451570A (en) * 1981-03-26 1984-05-29 The Regents Of The University Of California Immunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell line
US4608252A (en) * 1981-04-23 1986-08-26 Syntex (U.S.A.) Inc. Chloramphenicol derivatives antigens and antibodies
IL70686A (en) * 1983-01-20 1988-07-31 Suntory Ltd Mutant tumor cell lines for use in the preparation of hybridomas and the hybridomas obtained therefrom
HU188847B (en) * 1983-02-22 1986-05-28 Human Oltoanyagtermeloe Es Kutato Intezet,Hu Process for producing liophylized combined vaccines
NO162241C (en) * 1983-06-14 1989-11-29 Roussel Uclaf NEW RADIOACTIVE ESTRADIA DERIVATIVES LABELED WITH JOD125, THE PROCEDURE OF THEIR PREPARATION AND THEIR USE OF RADIO DIMMUNOLOGICAL RESEARCH AND QUANTITY DETERMINATION OF STEROIDS IN BIOLOGICAL LIQUIDS.
DE3483957D1 (en) * 1983-11-21 1991-02-21 Wellcome Found COMPLEX, METHOD FOR THEIR PRODUCTION AND FORMULATIONS CONTAINING THE SAME.
JPS60193925A (en) * 1984-03-13 1985-10-02 Chemo Sero Therapeut Res Inst Lyophilized pharmaceutical preparation vaccine
CA1224003A (en) * 1984-04-24 1987-07-14 Robert S. Molday Colloidal sized metal-polysaccharide particles
US4624921A (en) * 1984-04-26 1986-11-25 Cetus Corporation Human lymphoblastold cell line and hybridomas derived therefrom
US4624923A (en) * 1984-06-08 1986-11-25 Yeda Research And Development Company Limited Metal-coated polyaldehyde microspheres
US4882423A (en) * 1984-10-02 1989-11-21 Calpis Food Industry Substance-conjugated complement component C1q
US5035995A (en) * 1984-10-02 1991-07-30 Calpis Food Industry Co., Ltd. Test method involving substance-conjugated complement component C1q
US5019497A (en) * 1984-11-09 1991-05-28 Lennart Olsson Human squamous lung carcinoma cell specific antigens and antibodies
US4693975A (en) * 1984-11-20 1987-09-15 The Wistar Institute Human hybridroma fusion partner for production of human monoclonal antibodies
US4720459A (en) * 1985-02-14 1988-01-19 Medical College Of Wisconsin Research Foundation, Inc. Myelomas for producing human/human hybridomas
US4657763A (en) * 1985-09-03 1987-04-14 Michael Ebert Combined chrysotherapeutic agents for autoimmune diseases
JPS62162963A (en) * 1986-01-10 1987-07-18 Sadao Shiosaka Specific antibody of low molecular material prepared by using metallic colloid particle as carrier and preparation thereof
US4753873A (en) * 1986-02-03 1988-06-28 Cambridge Bioscience Corporation Peptides for the diagnosis of HTLV-III antibodies, their preparation and use
US4906564A (en) * 1987-03-13 1990-03-06 The United States Of America As Represented By The Secretary Of The Army Antigenic determinants recognized by antibodies obtained using a pathogenic agent or a derivative thereof that presents a restricted set of antigens
US4812556A (en) * 1987-05-18 1989-03-14 Virovahl Synthetic peptide antigen for the detection of HIV-2 infection
US4880750A (en) * 1987-07-09 1989-11-14 Miragen, Inc. Individual-specific antibody identification methods
US5017687A (en) * 1988-03-10 1991-05-21 Virovahl, S.A. Peptides for the detection of HTLV-1 infection
US5089424A (en) * 1988-06-14 1992-02-18 Abbott Laboratories Method and apparatus for heterogeneous chemiluminescence assay
US5047523A (en) * 1988-08-02 1991-09-10 Ortho Diagnostic Systems Inc. Nucleic acid probe for detection of neisseria gonorrhoea
US4977286A (en) * 1988-09-09 1990-12-11 Trustees Of The University Of Pennsylvania Glycolipids
SE462454B (en) * 1988-11-10 1990-06-25 Pharmacia Ab METHOD FOR USE IN BIOSENSORS
US5376556A (en) * 1989-10-27 1994-12-27 Abbott Laboratories Surface-enhanced Raman spectroscopy immunoassay
DE69125992T2 (en) * 1990-09-14 1997-08-21 Tosoh Corp Method and kit for immunoassay
US5466609A (en) * 1990-10-31 1995-11-14 Coulter Corporation Biodegradable gelatin-aminodextran particle coatings of and processes for making same
US5169754A (en) * 1990-10-31 1992-12-08 Coulter Corporation Biodegradable particle coatings having a protein covalently immobilized by means of a crosslinking agent and processes for making same
US5294369A (en) * 1990-12-05 1994-03-15 Akzo N.V. Ligand gold bonding
JP3220180B2 (en) * 1991-05-23 2001-10-22 三菱化学株式会社 Drug-containing protein-bound liposomes
US5248772A (en) * 1992-01-29 1993-09-28 Coulter Corporation Formation of colloidal metal dispersions using aminodextrans as reductants and protective agents
US5736410A (en) * 1992-09-14 1998-04-07 Sri International Up-converting reporters for biological and other assays using laser excitation techniques
CN1245156C (en) * 1993-02-22 2006-03-15 美国生物科学有限公司 Methods for in vivo delivery of biologics and compositions useful therefor
US6274552B1 (en) * 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US20010055581A1 (en) * 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5521289A (en) * 1994-07-29 1996-05-28 Nanoprobes, Inc. Small organometallic probes
US5874226A (en) * 1995-05-22 1999-02-23 H. Lee Browne In situ immunodetection of antigens
US5685578A (en) * 1995-09-25 1997-11-11 Versa Technologies, Inc. Locking mechanism for a trailer door
DE19622628A1 (en) * 1996-06-05 1997-12-11 Boehringer Mannheim Gmbh Stabilization of metal conjugates
US7229841B2 (en) * 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US6407218B1 (en) * 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
EP1039933B8 (en) * 1997-11-10 2006-12-20 Cytimmune Sciences, Inc. METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSE AND FOR THE PRODUCTION OF $i(IN VITRO) MABS
US5921927A (en) * 1997-11-12 1999-07-13 Axialtome Australia Pty. Ltd. Positioning method and apparatus for X-ray tomography
EP0922446A1 (en) * 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
JP3920462B2 (en) * 1998-07-13 2007-05-30 株式会社大和化成研究所 Aqueous solutions for obtaining noble metals by chemical reduction deposition
JP2000160210A (en) * 1998-11-25 2000-06-13 Mitsuboshi Belting Ltd Production of particulate
WO2001013957A2 (en) * 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
JP2003515438A (en) * 1999-12-03 2003-05-07 サーロメッド・インコーポレーテッド Hydroxylamine seeding of metal colloid nanoparticles
CN1450903A (en) * 2000-01-11 2003-10-22 特瓦制药工业有限公司 Processes for preparing clarithromycin polymorphs
US6530944B2 (en) * 2000-02-08 2003-03-11 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US6660058B1 (en) * 2000-08-22 2003-12-09 Nanopros, Inc. Preparation of silver and silver alloyed nanoparticles in surfactant solutions
JP2002080903A (en) * 2000-09-08 2002-03-22 Japan Science & Technology Corp Functional metallic fine particle with stabilized dispersion and semiconductor fine particle and method for producing the same
EP1401376B1 (en) 2001-04-30 2016-11-30 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US20040018203A1 (en) * 2001-06-08 2004-01-29 Ira Pastan Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
US6821529B2 (en) * 2001-09-05 2004-11-23 Deanna Jean Nelson Oligo(ethylene glycoll)-terminated 1,2-dithiolanes and their conjugates useful for preparing self-assembled monolayers
JP2003342742A (en) * 2002-05-23 2003-12-03 Risho Kogyo Co Ltd Electroless gold plating liquid
US20040204576A1 (en) * 2002-07-02 2004-10-14 Donald Jackson Polynucleotides encoding a novel human phosphatase, BMY_HPP13
WO2004013093A2 (en) * 2002-08-02 2004-02-12 Immunogen, Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
AU2004311630A1 (en) * 2003-12-02 2005-07-21 Cytimmune Sciences, Inc. Methods and compositions for the production of monoclonal antibodies
US20060222595A1 (en) * 2005-03-31 2006-10-05 Priyabrata Mukherjee Nanoparticles for therapeutic and diagnostic applications

Also Published As

Publication number Publication date
AU2005209318B2 (en) 2010-02-11
EP1715971A1 (en) 2006-11-02
EP1715971A4 (en) 2010-10-13
JP2007523067A (en) 2007-08-16
JP4833862B2 (en) 2011-12-07
IL177075A0 (en) 2006-12-10
AU2005209318A1 (en) 2005-08-11
CN1960825A (en) 2007-05-09
CA2554755A1 (en) 2005-08-11
US20050175584A1 (en) 2005-08-11
IL177075A (en) 2013-04-30
WO2005072893A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
WO2005072893A8 (en) Functionalized colloidal metal compositions and methods
WO2005046572A3 (en) Targeted delivery of controlled release polymer systems
WO2005110013A3 (en) Methods, compositions, and preparations for delivery of immune response modifiers
WO2006064453A3 (en) Targeting agents for molecular imaging
WO2005072061A3 (en) Conjugates for cancer therapy and diagnosis
EP2985281A3 (en) Isoindoline compounds for use in the treatment of cancer
WO2007113648A3 (en) Ctla4 antibody combination therapy
WO2004111192A3 (en) Targeted delivery to legumain-expressing cells
WO2004093795A3 (en) Compositions for delivery of drug combinations
WO2008039218A3 (en) Inhibitors of bruton's tyrosine kinase
WO2005112886A3 (en) Methods and articles for the delivery of therapeutic agents
WO2005011734A3 (en) Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
WO2006064451A3 (en) Targeting contrast agents or targeting therapeutic agents for molecular imaging and therapy
WO2007047291A3 (en) Anti-glypican-3 antibody
WO2007064945A3 (en) Cancer therapies and pharmaceutical compositions used therein
WO2006041641A3 (en) Therapeutic agents with decreased toxicity
WO2006108405A3 (en) Nanoparticle/active ingredient conjugate
WO2004063342A3 (en) Cellular delivery and activation polypeptide-nucleic acid complexes
WO2007077561A3 (en) Compositions and methods for enhancing in-vivo uptake of pharmaceutical agents
IL183274A0 (en) Method for producing sterile suspensions or lyophilisates of poorly soluble basic peptide complexes, pharmaceutical formulations containing the same, and use thereof as medicaments
WO2006033006A3 (en) Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor
WO2004074232A8 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2007059008A3 (en) N-substituted indenoisoquinolines and syntheses thereof
WO2008028965A3 (en) Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WR Later publication of a revised version of an international search report
WWE Wipo information: entry into national phase

Ref document number: 2005209318

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 177075

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2554755

Country of ref document: CA

Ref document number: 2006551620

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2225/KOLNP/2006

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005209318

Country of ref document: AU

Date of ref document: 20050128

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005209318

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005722715

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200580009719.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005722715

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 204120

Country of ref document: IL